Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor TargetBusiness Wire • 12/03/24
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsBusiness Wire • 11/27/24
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.Business Wire • 11/22/24
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/20/24
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary CholangitisBusiness Wire • 11/15/24
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowBusiness Wire • 11/13/24
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and PipelineBusiness Wire • 11/12/24
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised OutlookBenzinga • 11/07/24
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the EpidemicBusiness Wire • 11/07/24
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/06/24
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidanceMarket Watch • 11/06/24